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Abstract 
A new series of non peptide angiotensin (A-II) receptor antagonist has been 
prepared. This N-(biphenyl methyl) imidazoles e.g. Some new 4'-{5-amino-
2-[2-substituted-phenylamino)-phenyl-methyl]-benzimidazol-1-ylmethyl}-
biphenyl-2-carboxylic acid derivatives were synthesized by 2-( α -hydroxy 
benzyl) benzimidazole was converted to 2-(α-bromo benzyl) benzimidazole 
by reacting with HBr and Anhydrous ZnCl2 Schiff bases react with biphenyl 
carboxylic acid with different substituents amino group cyclocondensation 
with appropriate reagents. Differ from the previously reported and related 
compounds in that they produce a potent hypertensive effect. The compounds 
synthesized were identified by 1H NMR, 13C NMR, FAB Mass and FT-IR 
spectroscopic techniques. All compounds studied in this work were screened 
for their antihypertensive activity by tail cuff method and direct method 
measurement of blood pressure. 
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Introduction  
The octapeptide angiotensin II (Ang II) produced by 
the rennin angiotensin system (RAS) is a potent 
vasoconstrictor and thus plays an integral role in the 
pathophysiology of hypertension. This directed many 
researchers toward designing drugs to block the 
effects of Ang II either by inhibiting the angiotensin 
converting enzyme (ACE) or renin or by blocking the 
Ang II receptors. Ang II receptor antagonists have 
proved to lower blood pressure effectively, and they 
are better tolerated than other classes of drugs. The 
renin-angiotensin system (RAS) plays a key role in 
regulating cardiovascular homeostasis and electrolyte/ 
fluid balance in normotensive and hypertensive 
subjects [1]. Activation of renin-angiotensin cascade 
begins with renin secretion from the juxtaglomerular 
apparatus   of  the   kidney   and   culminates   in   the  
 
 
formation of the octapeptide angiotensin II (AII), 
which then interacts with specific receptors present in 
different tissues [2]. Two basic types of receptors, 
both having a broad distribution, have been 
characterized so far: the AT1 receptor, responsible for 
the majority of effects attributed to this peptide, and 
the AT2 receptor, with a functional role yet uncertain 
[3]. The main effects of AII are the regulation of 
blood pressure through vasoconstriction, thereby 
effecting an increase in vascular resistance, the 
regulation of volemia through the stimulated release 
of vasopressin and aldosterone, which induces saline 
retention, and the regulation of the 
adrenocorticotropic hormone (ACTH). Thus, 
reducing the levels of AII by inhibition of one of the 
RAS enzymes or  directly  blocking  the AII receptors  
is in theory a good approach for treating hypertension, 
confirmed by the success of angiotensin-converting 
enzyme (ACE) inhibitors as antihypertensives [4]. 
doi:10.5138/ijdd.2010.0975.0215.02038 
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Hypertension is one of the most important 
cardiovascular risk factor but its control is still 
Challenge for physicians all around the world. 
Antihypertensive are a class of drugs that are used in 
medicine and pharmacology to treat hypertension 
(high blood pressure). All Hypertensive drugs cause 
dizziness, ankle swelling, headache, fatigue, chest 
discomfort and cough. This review focus on the 
adverse effects of Antihypertensive drugs, severity of 
these adverse effects and attempts made to prevention 
and treatment of hypertension by non-
pharmacological intervention.Substantial effort has 
been made to find renin inhibitors, although orally 
active agents have only recently been reported [5]. 
The discovery of potent and orally active nonpeptide 
Ang II antagonists such as losartan and eprosartan has 
encouraged the development of a large number of 
similar compounds [6]. Among them, irbesartan, 
candesartan, valsartan, telmisartan, tasosartan,and 
olmesartan are on the market.  
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 Figure 1. Angiotensin II AT1 selective antagonists. 
 
 
 
 
Most of the developed AT1 receptor antagonists are 
characterized by the presence in their structure of the 
biphenyl fragment bearing an acidic moiety and differ 
in the nature of the pendent heterocyclic system 
(valsartan lacks the heterocyclic moiety) connected to 
the para position of the proximal phenyl.Substantial 
effort has been made to find renin inhibitors, although 
orally active agents have only recently been reported 
[7, 8]. No less effort has been devoted to finding AII 
antagonists, which besides being the most direct way 
of controlling the RAS could have the additional 
advantage of lacking the side effects, such as cough 
and angioedema, observed with ACE inhibitors, as 
these are probably caused by partial inhibition of the 
cleavage of bradykinin and substance P. Starting from 
the initial leads reported by Takeda [9] researchers at 
DuPont discovered losartan, the first orally active 
AT1 selective nonpeptide AII antagonist that reached 
the market for the treatment of hypertension (1994, 
Cozaar). The substituent at 6-position on the nucleus 
increases the activity whereas small substituent at 5-
position decreases the activity [10]. Compounds 
containing tetrazole nucleus are also reported as AT1 
receptor antagonists and their protypical derivative  
exhibits non-competitive antagonism [11] and amino 
group attach with carboxylic group given good 
biological activity [11-12].  In recent years, attention 
has increasingly been given to the synthesis of 
benzimidazole derivatives as a source of new 
antimicrobial agents. The synthesis of novel 
benzimidazole derivatives remains a main focus of 
medicinal research. Recent observations suggest that 
substituted benzimidazoles and heterocycles, which 
are the structural isosters of nucleotides owing fused 
heterocyclic nuclei in their structures that allow them 
to interact easily with the biopolymers, possess 
potential activity with lower toxicities in the 
antihypertensive activity approach [11-12].    
 
Experimental 
Melting points were determined in open capillary 
tubes and are uncorrected. The time required for 
completion of the reaction was monitored by TLC 
using Silica gel-G plates and spots were exposed in 
iodine chamber. IR spectra were recorded on a Perkin 
Elmer 1800 (FTIR) spectrometer 1H NMR spectra 
(DMSO) were taken on a DRX-300 spectrometer 
(300 MHz) using TMS as internal standard and 
chemical shifts are expressed in δ ppm.  
 
2-(α-hydroxy benzyl) benzimidazole[13, 14] 
In a 500ml of round bottom flask, equimolar amount 
of o-phenylene diamine (0.01 mol) and Mandelic acid 
(0.01 mol) were placed. 18 ml of 4n HCL was than 
added followed by a few porcelain chips and the 
mixture was refluxed gently on an oil-bath at 135-
140oC for 2 hours. The reaction mixture was then 
allowed to cool to room temperature, which was 
further neutralized with 20% Na2CO3 solution and 
was kept overnight. The crude product filtered at the 
vacuum pump, was recrystallized from ice-cold water 
or acetone. The formation of 2-( α -hydroxy benzyl) 
benzimidazole was confirmed by comparing its 
melting point with that reported in the literature, by 
thin layer chromatography and spectral analysis. 
Yield: 85%, m.p. =1220-1250C. Anal.Calcd for 
C14H12N2O:C,74.98;H, 5.39 ;N,12.49 
%;IR(KBr):1954,1297.6,1581,1375,1965.1HNMR(30
0Hz,CDCl3):2.54(s,1H,OH),4.98(s,1H,NH)5.26(m,1
H,C-H),7.10-8.23(m,9H,ArH), FAB-MS, 224.09  
 
MS-01 Synthesis of 2-(α-bromo benzyl) 
benzimidazole 
In a 250 ml round bottom flask fitted with a reflux 
condenser, (the top of which is connected to a device 
for absorbing hydrogen chloride gas) Zinc chloride 
(o.5 mole) and HBr (3ml) were placed and 2-(α –
hydroxy benzyl) benzimidazole (0.25 mol) was 
added. The mixture was refluxed gently at 125-130oC 
for 3 hours on an oil bath. The reaction mixture was 
then allowed to cool and the resulting bromide 
compound was separated. Refrigerated overnight and 
recrystallized successively from ice-cold water or 
acetone. 
Yield: 72 %, m.p. =1330-1350C. Anal.Calcd for 
C14H13N3:C,75.68;H, 5.46 ;N,18.91 
%;IR(KBr):1923,1562,1437,1353,1870,1933.1HNMR
(300Hz,CDCl3):2.89(s,2H,NH)5.22(m,1H,C-H),7.10-
8.23(m,10H,ArH),FAB-MS, 222.11  
 
MS-02- 5-Nitro-1H-benzimidazol-2-yl)-phenyl-
methanol 
5.5 ml of concentrated nitric acid was placed in three 
necked flask and equal quantity of concentrated 
sulphuric acid was added slowly. The mixture was 
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kept in the ice cold water then compound MCS-01 
(1.5 gm) was mixed in portions during 2.5 hours 
under room temperature.  
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After stirred continuously for 2.5 hours 15 minutes 
and then the reaction mixture was poured slowly over 
crushed ice with stirring. The precipitated product 
was filtered out and washes with cold water. The final 
product MCS-02 was formed. Product was (5-Nitro-
1H-benzimidazole-2-yl)-phenyl methanol then treated 
with various aromatic amines to obtain the Schiff 
bases compounds MCS-03. In a 250 ml round bottom 
flask fitted with a reflux condenser, (the top of which 
is connected to a device for absorbing hydrogen 
chloride gas) Zinc chloride (o.5 mole) and HBr (3ml) 
were placed and (5-Nitro-1H-benzimidazole-2-yl)-
phenyl methanol (0.25 mol) was added. The mixture 
was refluxed gently at 166-169oC for 5 hours on an 
oil bath. The reaction mixture was then allowed to 
cool and the resulting bromide compound was 
separated. Refrigerated overnight and recrystallized 
successively from ice-cold water or acetone. (5-Nitro-
1H-benzimidazole-2-yl)-phenyl methanol (0.01mole) 
was dissolved in anhydrous dioxane (15 ml) and 
excess of various substituted aromatic amines were 
added. The reaction mixtures were allowed to stand 
overnight at room temperature, the solutions were 
evaporated to dryness and gummy solid obtained was 
washed with cold water. The solids were then 
extracted with 2M HCl. The acidic extracts were 
made alkaline with NH4OH and the resultant 
products were recrystallized from ice-cold water or 
acetone. Some of these final derivatives were 
characterized as picrates. The melting points of all the 
title compounds were recrystallized by open capillary 
method and were found to be uncorrected. The 
compounds were obtained in comparatively good 
yield of 50-70%.’ 
 
MS 03: (Biphenyl Carboxylic acid) 
35 gm of potassium hydroxide was heated at 170°-
192 °C in a three necked flask until fusion. 12.5gm of 
finely powdered of 9H-Fluorenone was added in five 
portions over one and half hour with vigorous stirring 
and the temperature was maintained at 170°-192°C 
for further one half hour. The fusion mixture was then 
poured in ice cold water with stirring. The obtained 
suspension was filtered at vacuum  pump and then 
filtrate was acidify with HCl to pH-4.5 resulting in 
precipitation of by product which was filtered under 
suction wash with distilled water and the filtrate was 
again acidify with Con.HCl. The precipitated product 
was filtered under suction and dried in air. The 
product was recrystallized from Absolute ethanol. 
Product MCS-04 was formed. 
Yield:81%.m.p.=145-148°C.IR(KBr):3598-3069(O-
Hstr),1675.4(C=O Carboxylic, str), 1393, 1364.3(C-
O-H in-plane bend); 1H NMR(CDCl3): d 
10.03(1H,s,COOH),7.41-8.21(1H,m,9H),13CNMR 
(CDCl3)δ:112.4,116.8,126.8,133.5,162.8,FABMS,198
.08(100%),199.06(14.5%),200.12(1.%).Anal. Calcd 
for C13H7N10O2: C, 78.71; H, 5.05%,N,16.14; Found: 
C, 78.54; H, 4.97%,N,16.03 
 
MS-04: (4' Acetylamino methyl biphenyl-2-
caboxylic acid) 
5 gm of MCS 03 was dissolved in 25 ml of 
concentrated H2SO4.After that acetamide (2.15 gm) 
and Paraform aldehyde (0.560) gm were added 
subsequently. The solution was heated at 70°C along 
with stirring for 4.5 hours. The hot mixture was 
poured over ice and cold water. The precipitated 
product was filtered under suction and dried in air. 
The product was recrystallized from Absolute 
ethanol. The resulting solid was filtered out.Yield: 
58% m.p.-165o-169oC IR (KBr) (cm-1): 3397.4 (N-H 
str.), 3262.7(O-H, str), 2986 (C-H str), 2945 (aliphatic 
C-H str), 1675.2 (C=O str of), 1587.5 (N-H bend of 
amide), 1495.9(C-N str) 784.6(Benz. Ring); 1H NMR 
(300 MHz, CDCl3) δ:2.03(s,3H,CH3), 
9.76(1H,s,COOH),4.32(2H,s,CH2),7.98(s,1H,-NH); 
7.09-8.24(m,8H,ArH).13CNMR(CDCl3)δ:19.5(CH3), 
53.7(CH2)112.4,116.1,122.1,125.7,133.5,139.2,144.1,
155.7,170.2,FAB-MS, 269.12(100%), 270.03(18.6), 
271.07 (2.2%).Anal. Calcd for C16H15NO3: C, 71.36; 
H, 5.61; N, 5.20%; Found: C, 71.27; H, 5.54; N, 5.12 
 
MS 05: (4'-chloro-methylbiphenyl-2-carboxylic 
acid) 
1.4gm of MCS-04 was taken in a RBF. 1.598 gm of 
phosphorus oxy chloride was added to 4ml of DMF 
and further addition of xylene (4ml). The reaction 
mixture was refluxed for 7 ½ hours. The cold solution 
was washed with water and evaporated to give a light 
yellow crystalline product.Yield: 52 % m.p.-133o-
136oC IR (KBr) (cm-1): IR (KBr): 3354 (O-H str.), 
2902(C-H str., CH2), 1679.4 (Carboxylic, C=O str.), 
1676-1413 (C=N, C=C str.), 1189 (C-O str), 854.2 
(.benz. ring), 598.7(C-Cl str.) 1H NMR (300 MHz, 
CDCl3) 10.07(s, 1H, OH), 
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7.118.05(m,8H,ArH),4.64(s,2H,CH2)..13CNMR(CDCl
3)δ:33.8(CH2)115.9,117.2,123.4,128.2,136.1,139.2,14
2.4,151.2,,FABMS,289.12(100%)291.14(97.11%),27
0.03(18.6),271.07 (2.2%).Anal.Calcd for C14H11BrO2: 
C, 57.76; H, 3.81; %; Found: C, 57.71; H, 3.80; %. 
 
MS- 06-   4'-{2-[2-substituted-phenylamino)-
phenyl-methyl]-5-nitro-benzimidazol-1-ylmethyl}-
biphenyl-2-carboxylic acid 
345 mg of MCS-02 was dissolved in 20ml of DMF 
(dimethyl formamide) and stirred vigorously with 
5.78 gm of potassium carbonate at 400C for three half 
hours. To the resulting mixture 0.482gm of MCS-06 
first dissolved in 20 ml of DMF and then was added 
drop wise with dropping funnel in 1 hour the reaction 
was allowed to proceed for further 8 hours at room 
temperature and solvent removed under vacuum. 
Residue was treated with 20ml of dilute HCl and 
extracted with ethyl acetate. The organic layer was 
washed with water, distilled water and dried over 
anhydrous sodium sulphate. The solvent was 
evaporated and solid (MS-06) was obtained.  
 
MCS-07: 4'-{5-amino-2-[2-substituted-phenyl 
amino)-phenyl-methyl]-benzimidazol-1-ylmethyl}-
biphenyl-2-carboxylic acid 
1.75 gm [Different substitute amines MS-06] of 
compound was placed in three necked RBF and 
dissolved in absolute ethanol and heated to 600C 
under reflux. To 5.25 gm stannous chloride 
dehydrates was added with slow stirring during five 
hours and reaction conditions were maintained for 
further 12 hours. The mixture was cooled to room 
temperature and pH adjusted to 7.6 with 5% sodium 
hydroxide solution. The organic layer was washed 
with brine, distilled water then dried over anhydrous 
sodium sulphate. Solvent removed under vacuum and 
product was obtained. 
 
[1] 4'-{5-amino-2-[2-chloro-phenylamino)-phenyl-
methyl]-benzimidazol-1-ylmethyl}-biphenyl-2-
carboxylic acid 
Yield:72%,m.p.=1440-1470C.Molecular weight 
559.06, Anal.Calcd for 
C34H27ClN4O2:C,73.05;H,4.87;N,10.02 %; IR (KBr): 
3517,3243,3436,3065, 1515,1715,655.2  1HNMR 
(300 MHz, CDCl3) 10.12(s, 1H, COOH), 4.31 (s, 
1H,NH),6.85-8.72 (m,21H,-ArH), 4.89 (s,2H,CH2). 
4.05 (s, 2H, arm-NH). 13CNMR 
(CDCl3)δ:52.8,111.1,112.5,114.1,121.2,123.5,128.2,1
30.2,133.1,134.3,135.2,138.4,144.4, FAB-MS, 558.18 
 
[2] 4'-{5-amino-2-[3-chloro-phenylamino)-phenyl-
methyl]-benzimidazol-1-ylmethyl}-biphenyl-2-
carboxylic acid 
Yield:76%,m.p.=1410-1420C.Molecular weight 
559.06, Anal.Calcd for C34H27ClN4O2: C,73.05;H, 
4.87;N,10.02 %; IR (KBr): 3512,3223, 3414,3054, 
1511,1710,651.5 1HNMR (300 MHz, CDCl3) 10.16(s, 
1H, COOH), 4.35 (s, 1H,NH),6.86-8.74 (m,21H,-
ArH), 4.97 (s,2H,CH2).4.11(s, 2H, arm-NH). 13CNMR 
(CDCl3)δ:52.8,111.1,112.5,114.1, 121.2,123.5, 128.2, 
130.2,133.1,134.3,137.1,138.4,140.1,FABMS, 559.87 
 
[3] 4'-{5-amino-2-[4-chloro-phenylamino)-phenyl-
methyl]-benzimidazol-1-ylmethyl}-biphenyl-2-
carboxylic acid 
Yield:70%,m.p.=1360-1380C.Molecular weight 
559.06, Anal.Calcd for 
C34H27ClN4O2:C,73.05;H,4.87;N,10.02 %; IR (KBr): 
3504,3243,3404,3048, 1518,1712,650.1 1HNMR (300 
MHz, CDCl3) 10.14(s, 1H, COOH), 4.39 (s, 
1H,NH),6.68-8.21 (m,21H,-ArH), 4.89 (s,2H,CH2). 
4.15 (s, 2H, arm-NH). 13CNMR 
(CDCl3)δ:52.8,111.1,112.5,114.1,121.2,123.5,128.2,1
30.2,133.1,134.3,137.1,139.4,141.5, FAB-MS, 560.11 
 
[4] 4'-{5-amino-2-[2-nitro-phenylamino)-phenyl-
methyl]-benzimidazol-1-ylmethyl}-biphenyl-2-
carboxylic acid 
Yield:82%,m.p.=1360-1380C.Mol.wt569.61, 
Anal.Calcd for C34H27N5O4: C,71.65;H,4.77; 
N,12.30%; IR (KBr):3519,3461,3065, 1643,1518, 
1703. 1HNMR (300 MHz, CDCl3) 9.87 (s, 1H, 
COOH), 4.33 (s, 1H,NH),6.99-8.56 (m,21H,-
ArH),4.98(s,2H,CH2) 4.03(s,2H,arm-NH).13CNMR 
(CDCl3)δ: 56.7,112.8, 113.4,116.2,117.2,126.5, 
130.1,132.133.8,135.1, 136.3,FAB-MS, 570.21 
 
[5] 4'-{5-amino-2-[3-nitro-phenylamino)-phenyl-
methyl]-benzimidazol-1-ylmethyl}-biphenyl-2-
carboxylic acid 
Yield:80%,m.p.=1310-1320C.Mol.wt569.61, 
Anal.Calcd for C34H27N5O4:C,71.65;H,4.77;N,12.30 
%; IR (KBr): 3526, 3460,3088, 1532,1544,1697. 
1HNMR (300 MHz, CDCl3) 9.83(s, 1H, COOH), 4.30  
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(s, 1H,NH),7.05-8.62 (m,21H,-ArH),4.92(s,2H,CH2) 
4.08(s,2H,arm-NH).13CNMR (CDCl3)δ: 53.1, 55.3, 
61.1, 70.7,111.4,113.1,113.5, 114.1, 121.2, 
135.5,137,FAB-MS, 570.83 
 
[6] 4'-{5-amino-2-[4-nitro-phenylamino)-phenyl-
methyl]-benzimidazol-1-ylmethyl}-biphenyl-2-
carboxylic acid 
Yield:79%,m.p.=1280-1300C.Mol.wt569.61, 
Anal.Calcd for C34H27N5O4:C,71.65;H,4.77;N,12.30 
%; IR (KBr): 3611, 3439,2965, 1515,1634,1699. 
1HNMR (300 MHz, CDCl3) 9.80(s, 1H, COOH), 4.28 
(s,1H,NH),7.00-8.54(m,21H,-ArH),4.92(s,2H,CH2) 
4.08 (s,2H,arm-NH).13CNMR (CDCl3)δ: 52.5,111.1, 
112,114,115.2,119.3,124.5,126.0, 127.2,127.5,127.9, 
133.2,134.2,138.4,FAB-MS, 570.83 
 
[7] 4'-{5-amino-2-[2, 4-dichloro-phenylamino)-
phenyl-methyl]-benzimidazol-1-ylmethyl}-
biphenyl-2-carboxylic acid 
Yield:61%,m.p.=1820-1850C.Mol.wt593.50, 
Anal.Calcd for C34H26Cl2N4O2:C,68.81;H,4.42;N,9.44 
%; IR (KBr): 3578, 3466,2937, 1586,1645,1718. 
1HNMR (300 MHz, CDCl3) 10.78(s, 1H, COOH), 
4.28 (s, 1H,NH),7.22-8.27(m,20H,-ArH),4.97 (s,2H, 
CH2)4.14(s,2H,arm-NH).13CNMR(CDCl3)δ: 58.0, 
112.9, 113.4,116.2,121.1,128.4, 135.5, 137.2, 
139.8,FAB-MS, 592.16 
 
[8] 4'-{5-amino-2-[2,3-dichloro-phenylamino)-
phenyl-methyl]-benzimidazol-1-ylmethyl}-
biphenyl-2-carboxylic acid 
Yield:65%,m.p.=1880-1910C.Mol.wt593.50, 
Anal.Calcd for C34H26Cl2N4O2:C,68.81;H,4.42;N,9.44 
%; IR (KBr): 3544, 3475,2912, 1543,1648,1722. 
1HNMR (300 MHz, CDCl3) 10.83(s, 1H, COOH), 
4.23 (s, 1H,NH),7.28-8.44(m,20H,-
ArH),4.91(s,2H,CH2)4.18(s,2H,arm-NH).13CNMR 
(CDCl3)δ: 52.5,111.1,112,114.2,115.1,116.6, 120.1, 
122.5,122.9,133.2,134.2,136,137.5,FAB-MS, 594.31 
 
[9] 4'-{5-amino-2-[2,5-dichloro-phenylamino)-
phenyl-methyl]-benzimidazol-1-ylmethyl}-
biphenyl-2-carboxylic acid 
Yield:62%,m.p.=1880-1790C.Mol.wt593.50, 
Anal.Calcd for C34H26Cl2N4O2:C,68.81;H,4.42;N,9.44 
%; IR (KBr): 3542, 3478,2933, 1541,1641,1720. 
1HNMR (300 MHz, CDCl3) 10.81(s, 1H, COOH), 
4.27 (s, 1H,NH),7.13-8.48(m,20H,-
ArH),4.98(s,2H,CH2)4.16(s,2H,arm-NH).13CNMR 
(CDCl3)δ: 52.5,111.1,112,114.2,115.1,116.6, 120.1, 
122.5,122.9,133.2,134.2,136,139.1,FAB-MS, 594.31 
 
[10] 4'-{5-amino-2-[2,5-nitro-phenylamino)-phenyl 
-methyl]-benzimidazol-1-ylmethyl}-biphenyl-2-
carboxylic acid 
Yield:58%,m.p.=2340-2370C.Mol.wt  614.61, 
Anal.Calcd for C34H26N6O6:C,66.44;H,4.26;N,13.67 
%; IR (KBr): 3597-3121, 3444,2912, 
1532,1630.1,1711. 1HNMR (300 MHz, CDCl3) 
10.66(s, 1H, COOH), 4.14 (s, 1H,NH),7.33-
8.71(m,20H,-ArH),4.95(s,2H,CH2)4.19(s,2H,arm-
NH).13CNMR (CDCl3)δ: 55.4,112.1,113.4,114.1, 
116.3,119.2,128.2,134.2,139.7,FAB-MS, 614.19 
 
[11] 4'-{5-amino-2-[2,4-nitro-phenylamino)-phenyl 
-methyl]-benzimidazol-1-ylmethyl}-biphenyl-2-
carboxylic acid 
Yield:58%,m.p.=2340-2370C.Mol.wt  614.61, 
Anal.Calcd for C34H26N6O6:C,66.44;H,4.26;N,13.67 
%; IR (KBr): 3594-3129, 3441,2910, 1532, 
1654.1,1707. 1HNMR (300 MHz, CDCl3) 10.63(s, 
1H, COOH), 4.11 (s, 1H,NH),7.30-8.61(m,20H,-
ArH),4.95(s,2H,CH2)4.19(s,2H,arm-NH).13CNMR 
(CDCl3)δ: 55.4,112.1,113.4,114.1, 116.3,119.2,128.2, 
134.2,139.7,140.1,142.4,FAB-MS, 615.10 
 
[12] 4'-{5-amino-2-[2-methoxy-phenylamino)-
phenyl-methyl]-benzimidazol-1-ylmethyl}-
biphenyl-2-carboxylic acid 
Yield:63%,m.p.=2740-2770C.Mol.wt  554.64 
Anal.Calcd for C35H30N4O3:C,75.79;H,5.45;N,10.10 
%; IR (KBr): 3613-3150, 3443, 2932,2832, 
1526,1640, 1654.1,1719. 1HNMR (300 MHz, CDCl3) 
10.93(s, 1H, COOH), 4.11 (s, 1H,NH),7.35-8.78 
(m,21H,-ArH), 4.95(s,2H,CH2)3.76(s,3H,CH3) 
4.19(s,2H,arm-NH).13CNMR (CDCl3)δ: 23.7,53.6, 
111.1,112.5, 112.7,114.5,116.1,119.1,123.1, 136.2, 
139.1, 145,FAB-MS, 554.21 
 
[13] 4'-{5-amino-2-[3-methoxy-phenylamino)-
phenyl-methyl]-benzimidazol-1-ylmethyl}-
biphenyl-2-carboxylic acid 
Yield:58%,m.p.=2830-2860C.Mol.wt  554.64 
Anal.Calcd for C35H30N4O3:C,75.79;H,5.45;N,10.10 
%; IR (KBr): 3567-3286, 3432,2914,2849, 
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1511,1632, 1714.7. 1HNMR (300 MHz, CDCl3) 
10.84(s, 1H, COOH), 4.03 (s, 1H,NH),7.14-
8.52(m,21H,-ArH), 5.04(s,2H,CH2)3.74 (s,3H,CH3) 
4.18(s,2H,arm-NH).13CNMR (CDCl3)δ: 14.5, 54.4, 
112.1,113.5,115.1,119.1,126,133.1,139.3,141.3,FAB-
MS, 553.53 
 
[14] 4'-{5-amino-2-[4-methoxy-phenylamino)-
phenyl-methyl]-benzimidazol-1-ylmethyl}-
biphenyl-2-carboxylic acid 
Yield:51%,m.p.=2910-2930C.Mol.wt  554.64 
Anal.Calcd for C35H30N4O3:C,75.79;H,5.45;N,10.10 
%; IR (KBr): 3611-3158, 3465, 2923,2887, 
1521,1647, 1650.1,1709. 1HNMR (300 MHz, CDCl3) 
10.63(s, 1H, COOH), 4.11 (s, 1H,NH),7.35-8.78 
(m,21H,-ArH), 4.95(s,2H,CH2)3.76(s,3H,CH3) 
4.19(s,2H,arm-NH).13CNMR (CDCl3)δ: 23.7,53.6, 
111.1,112.5, 112.7,114.5,116.1,119.1,123.1,136.2, 
139.1,145,FAB-MS, 555.04 
 
[15] 4'-{5-amino-2-[2-ethoxy-phenylamino)-phenyl 
-methyl]-benzimidazol-1-ylmethyl}-biphenyl-2-
carboxylic acid 
Yield:48%,m.p.=3150-3160C.Mol.wt  568.66 
Anal.Calcd for C36H32N4O3:C,76.04;H,5.67;N,9.85 
%; IR (KBr): 3567-3283, 3414,2987.2, 2859, 1528-
1640, 1675.1,1696.5. 1HNMR (300 MHz, CDCl3) 
10.96(s, 1H, COOH), 4.11 (s, 1H,NH),7.12-8.65 
(m,21H,-ArH), 3.94 (s,2H,CH2),4.91(s,2H,methylene-
CH2)1.63(s,3H,CH3)4.19(s,2H,arm-NH).13CNMR 
(CDCl3)δ: 14.6,55.3, 56.4,112.1,113.5,115.1,119.1, 
126,133.1,139.3,144.4,FAB-MS, 567.96 
 
[16] 4'-{5-amino-2-[3-ethoxy-phenylamino)-phenyl 
-methyl]-benzimidazol-1-ylmethyl}-biphenyl-2-
carboxylic acid 
Yield:52%,m.p.=3170-3190C.Mol.wt  568.66 
Anal.Calcd for C36H32N4O3:C,76.04;H,5.67;N,9.85 
%; IR (KBr): 3561-3288, 3417,2985.9, 2867, 1528-
1647, 1670.1,1698. 1HNMR (300 MHz, CDCl3) 
10.95(s, 1H, COOH), 4.15 (s, 1H,NH),7.16-8.60 
(m,21H,-ArH), 3.98 (s,2H,CH2),4.99(s,2H,methylene-
CH2)1.65(s,3H,CH3)4.13(s,2H,arm-NH).13CNMR 
(CDCl3)δ: 14.7,55.0, 54.1,110.8,112.3,114.2, 
123.2,124.2,129.2,139.8,FAB-MS, 567.96 
[17] 4'-{5-amino-2-[4-ethoxy-phenylamino)-phenyl 
-methyl]-benzimidazol-1-ylmethyl}-biphenyl-2-
carboxylic acid 
Yield:45%,m.p.=3220-3260C.Mol.wt  568.66 
Anal.Calcd for C36H32N4O3:C,76.04;H,5.67;N,9.85 
%; IR (KBr): 3561-3288, 3417,2985.9, 2867, 1528-
1647, 1670.1,1699.7 1HNMR (300 MHz, CDCl3) 
10.98(s, 1H, COOH), 4.18 (s, 1H,NH),7.10-8.67 
(m,21H,-ArH), 3.95 (s,2H,CH2),4.99(s,2H,methylene-
CH2)1.65(s,3H,CH3)4.13(s,2H,arm-NH).13CNMR 
(CDCl3)δ: 14.7,55.0, 54.1, 110.8,112.3,114.2,123.2, 
124.2,129.2,139.3,145.7,FAB-MS, 569.43 
 
Biological Activity: [12,15-19] 
Method [A]: Albino rats weighing 200-250 gm were 
used to screening for all the synthesized 
benzimidazoles derivatives for antihypertensive 
activity. Suspension of test compound was prepared 
in 1% w/v sodium carboxy methyl cellulose and 
administered at dose level of 50 mg/kg animal body 
weight to different of five rats each group. Contorl 
group received an equal quantity of 1% w/v sodium 
carboxy methyl cellulose suspension.  
After administration of dose to animal, blood pressure 
was measured by Non-invasive Tail cuff Method 
using pressure meter. Measurements were done after 
1 hour and 3 hour time interval intensive stepwise.  
One hour after administration of drug sample, animal 
was shifted to the restrainers, which restricts the 
movement of animal. The tail was cleaned with moist 
cotton to remove the dirty matter and talcum powder 
was sprayed on tail to make its surface smooth. A tail 
cuff and pulse transducer was fixed around the tail.  
 
Initially animal shows particular pulse level, when the 
pulse rate is within the normal range. ‘STRAT’ 
switch is put on and the recorder records the blood 
pressure as SBP (systolic blood pressure). DBP 
(Diastolic blood pressure) and MABP (mean arterial 
blood pressure), which is displayed on monitor. The 
pressure can be easily read from the pre-calibrated 
monitor. Once all the values are displayed the 
recorder is switched off and for next measurement. 
Some procedures are allowed once when sufficient 
pulse level is attained. Observations are given in the 
table1 and 2. 
 
Table 1. Hypertension induced in normotensive 
rat. 
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After 1hour After 3 hour Comp. Exp. 
Animal 
Albino 
(Wistar) 
Rat 
SBP DBP MABP SBP DBP MABP 
1 140 105 124 139 104 120 
2 143 108 123 138 103 121 
3 141 116 127 139 104 122 
4 139 112 122 142 108 125 
 [1] 
5 135 109 124 138 102 120 
1 138 112 125 138 100 119 
2 139 102 122 143 100 121 
3 148 104 124 143 102 122 
4 146 112 128 137 101 118 
 [2] 
5 143 108 126 140 103 121 
1 149 101 125 143 101 121 
2 144 109 131 140 100 120 
3 142 102 124 143 101 122 
4 145 105 125 145 100 121 
 [3] 
5 136 113 124 142 101 121 
1 141 104 123 137 106 121 
2 135 101 118 136 107 121 
3 140 110 125 138 112 125 
4 141 103 122 135 109 122 
 [4] 
6 133 113 123 141 109 125 
1 141 112 123 139 96 117 
2 140 103 124 145 98 119 
3 141 108 124 140 103 121 
4 145 113 128 144 102 123 
 [5] 
5 143 111 125 143 100 121 
1 141 114 126 139 102 120 
2 140 112 126 143 100 122 
3 144 116 130 145 98 119 
4 144 106 125 144 100 122 
 [6] 
5 145 112 126 139 100 120 
1 140 102 123 140 100 120 
2 137 101 124 146 100 123 
3 142 108 125 142 102 120 
4 143 105 124 139 104 121 
 
 [7] 
5 141 101 126 143 104 120 
1 144 111 126 143 100 119 
2 147 114 127 140 100 120 
3 142 116 125 139 101 121 
4 141 116 126 140 101 120 
 [8] 
5 140 113 124 143 102 121 
1 142 115 127 135 98 118 
2 140 106 123 142 101 121 
 [9] 
3 142 108 125 141 102 120 
4 144 112 126 141 102 121 
5 143 114 125 142 102 122 
1 141 116 128 142 112 122 
2 145 111 128 140 107 123 
3 143 115 129 138 106 122 
4 147 107 127 141 102 123 
 [10] 
5 152 110 131 142 106 124 
1 144 106 125 140 102 121 
2 148 104 126 142 106 124 
3 140 116 128 139 104 122 
4 148 106 126 144 104 124 
 [11] 
5 145 113 129 144 100 122 
1 149 111 130 143 106 124 
2 152 112 133 145 103 124 
3 150 111 131 146 104 125 
4 148 112 130 144 102 123 
 [12] 
5 144 114 129 146 106 126 
1 142 102 124 143 101 122 
2 145 105 125 145 100 121 
3 136 113 124 142 101 121 
4 139 113 122 140 100 120 
 [13] 
5 139 105 123 138 198 118 
1 144 112 132 142 104 123 
2 146 114 12 143 101 122 
3 142 112 127 140 102 121 
4 144 116 130 141 101 122 
 [14] 
5 142 110 126 139 104 123 
1 142 113 125 142 102 122 
2 141 109 123 144 101 121 
3 144 114 129 141 104 120 
4 146 104 132 142 100 121 
 
 
   [15] 
 
 
 
5 148 104 125 145 102 123 
1 142 114 127 140 101 122 
2 148 104 126 144 104 124 
3 154 108 132 144 102 123 
4 148 104 126 142 100 121 
 
 
[16] 
 
5 144 112 127 141 102 121 
1 144 106 125 142 101 123 
2 142 108 125 138 100 119 
3 140 104 122 144 106 125 
4 142 106 124 140 106 121 
 
 
[17] 
 
5 146 104 125 144 104 120 
Control Losartan 112 - - - - - 
Table 2. Reduction in blood pressure (mm Hg) at a 
dose of 50 μgm/kg animal body weight. 
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After 1hour After 3 hour Comp. Exp. 
Animal 
Albino 
(Wistar) 
Rat 
SBP DBP MABP SBP DBP MABP 
1 126 101 113 124 104 114 
2 125 105 115 122 100 112 
3 124 101 112 124 100 112 
4 122 100 111 121 103 112 
[1] 
5 124 102 113 124 106 115 
1 122 103 112 122 105 114 
2 126 100 113 121 101 111 
3 124 101 112 122 102 114 
4 128 105 114 121 103 112 
[2] 
5 126 100 113 124 101 112 
1 123 102 112 123 102 111 
2 124 102 113 125 102 112 
3 122 104 112 125 101 113 
4 123 102 113 128 103 112 
[3] 
5 121 101 113 123 102 111 
1 122 100 111 126 104 115 
2 128 102 115 130 103 116 
3 125 105 115 127 101 114 
4 120 102 111 123 101 112 
[4] 
5 125 103 114 126 100 113 
1 122 100 111 128 103 114 
2 123 107 115 125 100 112 
3 126 103 114 126 96 111 
4 129 101 115 119 104 111 
[5] 
5 123 107 115 121 99 110 
1 127 105 116 125 105 115 
2 132 96 114 130 101 116 
3 127 105 118 126 105 115 
4 129 108 124 124 104 114 
[6] 
5 122 112 121 122 103 112 
1 126 114 124 128 107 117 
2 124 111 121 123 104 113 
3 126 104 115 127 107 117 
4 127 105 114 126 105 115 
 
[7] 
5 129 108 118 124 104 114 
1 124 111 118 123 104 113 
2 126 104 117 127 107 117 
3 127 105 119 126 105 115 
4 129 108 119 124 104 114 
[8] 
5 122 112 117 122 103 112 
1 122 103 113 120 100 111 
2 120 100 110 122 102 112 
[9] 
3 122 102 112 121 101 111 
4 121 100 111 124 103 113 
5 122 103 114 121 104 112 
1 121 106 113 126 102 114 
2 126 106 112 128 102 115 
3 124 106 115 123 103 113 
4 126 104 115 124 104 114 
[10] 
5 124 108 116 122 102 112 
1 128 104 115 122 102 111 
2 126 105 116 121 104 113 
3 129 104 117 124 104 114 
4 127 102 115 127 102 115 
[11] 
5 126 108 118 122 107 113 
1 127 101 114 126 106 116 
2 125 105 130 123 105 114 
3 128 109 119 124 102 113 
4 131 103 117 128 103 115 
[12] 
5 134 102 118 125 106 116 
1 124 105 115 125 106 116 
2 122 109 116 126 106 116 
3 123 103 116 124 110 117 
4 125 104 115 125 106 116 
[13] 
5 122 105 116 131 106 118 
1 129 101 115 119 104 111 
2 121 101 113 123 102 111 
3 126 102 111 124 101 112 
4 121 100 110 125 102 111 
[14] 
5 126 103 115 122 103 112 
1 126 104 115 125 105 115 
2 124 104 114 121 100 110 
3 125 102 112 128 100 114 
4 124 102 113 128 100 114 
 
[15] 
5 128 102 115 129 101 115 
1 127 101 116 125 105 110 
2 124 102 119 128 102 111 
3 127 109 123 124 102 113 
4 125 110 122 127 101 114 
[16] 
5 124 112 118 121 102 112 
1 124 103 114 126 105 113 
2 125 102 113 124 101 112 
3 127 103 115 125 102 114 
4 124 104 114 128 101 113 
[17] 
5 122 102 111 123 102 112 
Control 
 
Losartan 
 
112 - - - - - 
Method [B] [21-22] 
Male albino wistar (150-250 gm) rats were used and 
housed at 24±10C room temperature. The rats were 
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anaesthetized with sodium chloride 0.9% solution, 
Drug solution 10-μg/100ml, and Heparin 500 
I.U.solution urethane hydrochloride 50% w/v solution 
80 mg/kg i.p. To set up the instrument firstly the level 
of mercury in the left arm of manometer was adjusted 
to 90-100 mm of Hg (normal blood pressure of 
rat).this was done in steps of 10mm at a time and the 
physiogram so obtained was used as calibration graph 
for calculations. The Jugular vein and carotid artery 
were surgically cannulated for drug administration for 
recording the blood pressure respectively. The trachea 
was cannulated in order to provide artificial 
respiration to rat during the experiment. By means of 
three way stop cock and a stainless steel needle at the 
end of P.E. tubing was attached to arterial cannula for 
B.P., Transducers and the venus cannula to a syringe. 
Then both the cannulas were filled by heparinized 
saline before the administration. Arterial cannula was 
connected via transducer to physiograph recorder. 
Several baseline readings of systolic and diastolic 
pressures were recorded. The physiograph shows the 
reduction of the blood pressure with compare to 
losratan. Synthesized compounds were screened in 
presence of Angiotensin II induced hypertension (0.5 
μg/kg i.v.). Observations are given in table 3 and 4. 
 
 
Table 3. Blood Pressure values for synthesized compounds over duration of 90 minutes. 
 
                                           Mean Arterial Pressure After Comp. 
No.  0 min. 10 min. 20 min. 30 min. 40 min. 50 min. 60 min. 70 min. 80 min. 90 min. 
Losartan 170 168 160 154 147 141 135 128 120 113 
1 172 163 156 149 141 133 126 120 114 112 
2 179 170 167 161 156 148 142 137 131 125 
3 175 171 163 157 151 145 138 131 123 111 
4 181 176 170 162 154 146 139 130 125 122 
5 173 168 159 148 142 135 129 122 117 110 
6 171 160 154 148 141 135 126 119 114 109 
7 168 164 159 152 147 141 137 132 129 124 
8 172 164 156 148 142 138 131 125 117 112 
9 181 177 170 162 156 149 142 135 131 126 
10 175 170 164 156 150 143 138 130 122 113 
11 183 176 170 163 157 150 142 137 131 128 
12 175 168 161 155 150 144 137 131 124 113 
13 170 164 158 152 147 140 133 127 121 114 
14 174 168 160 155 149 141 134 129 125 122 
15 177 169 160 152 145 140 132 125 118 111 
16 175 168 159 150 146 141 136 132 129 126 
17 176 170 162 159 150 143 137 128 119 110 
 
 
Results and discussion 
Results and discussion 
Step II include the novel sequential combination of 
three routine reactions to synthesize 2’- 
carboxybiphenyl methylene chloride. Biphenyl –2-
carboxylic acid  was prepared by potash fusion of 9H 
flourenone which was then subjected to aromatic 
substitution reaction using paraformaldehyde and 
acetamide in conc. sulphuric acid to affect 
intermediate,4-acetamidomethyl biphenyl-2’-
carboxylic acid. The required component was 
identified as third fraction which was subjected to 
substitution reaction with phosphorus oxychloride in 
xylene and dimethyl formamide to produce the 
pendant moiety 4-(bromomethyl) biphenyl-2’-
carboxylic acid and synthesis biphenyl with 
carboxylic compound [12, 19, 20]. Almost all the 
newly synthesized substituted 5th position attach 
amino group showed good antihypertensive activity 
with the goal of investigating the structure–activity 
relationships of benzimidazole.Synthesis has been 
carried out of selected benzimidazole derivatives 
having electron donor and acceptor substituents at 5-
position amino group and 2-postions different amines 
groups and their authencity and purity have been 
established through appropriate spectral and 
chromatographic techniques. The synthesized 
compounds were characterized on the basis of 
chemical and spectral data. Step I involved synthesis 
of aniline substituents benzimidazoles by 
condensation reaction of o-phenylenediamine with the 
respective hydroxy phenyl acetic acid then 
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corresponding react with hydrogen bromide in 
presence of anhydrous zinc chloride with phenyl 
amino derivatives were prepared by under controlled 
temperature conditions.   
 
Table 4. Antihypertensive activity of synthesized 
compounds.  
 
Compound. 
No 
Minimum 
Blood 
pressure 
value(mm Hg) 
Duration of 
hypertension 
effect(min.) 
Losratan 113 90 
1 112 90 
2 114 107 
3 111 92 
4 114 105 
5 110 90 
6 109 90 
7 113 105 
8 112 90 
9 117 110 
10 113 90 
11 111 115 
12 110 90 
13 110 95 
14 115 105 
15 111 90 
16 116 105 
17 110 90 
 
The present work was mainly intended to establish 
the moieties which are responsible for Angiotension-
II inhibition. Ang II antagonism by compounds with 
same functional group at 2 position has been found to 
be a function of substitute at 5-position. Presence of 
amino group has increased the activity substantially 
over the substituted one ([1] to [17]). The maximum 
activity has been observed with amino group 
(Compound 1, 3, 5, 6, 8, 10, 12, 14, 15, and 17). This 
suggests that there are some sites in the receptor 
pocket, which can interact with the functional groups 
at position 2-Substituted benzimidazole nucleus 
coupled to carboxylic biphenyl group has been 
designed, synthesized and evaluated for angiotensin II 
antagonism. Biological activity of synthesized 
compounds was carried out using rat blood pressure 
measurement experiment; the maximum fall blood 
pressure produced by Losartan is from value 172mm 
Hg to 113 mm Hg over a period 90 minutes 
.compounds number, 5, 8,9 also duration 90 minutes. 
The compounds reported in this paper Compound 1, 
3, 5, 6, 8, 10, 12, 14, 15, and 17were the final 
compound and prepared for antihypertensive activity. 
Taking Losartan as lead compound we had fused the 
benzene ring with imidazole and coupling reaction 
with 4-chloromethyl biphenyl 2’- carboxylic acid 
(SR-5) to get the resulting compounds which shows 
hypertensive standard compared with our synthesis 
molecules activity. In the biphenyl ring carboxylic 
group at ortho position is necessary for 
pharmacological activity. had the best 
pharmacological activity was found in the literature. 
At position 5 of benzimidazole NH2 group gives 
good activity.    
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